MAP2K7 and colorectal cancer: For example, in the case of PD-0325901 (mirdametinib, an investigational MEK inhibitor [40]), high performance was achieved in the cases of colorectal cancer (BA = 1.0 for 13 sensitive and 1 resistant cell line), lung adenocarcinoma (BA = 0.91 for 17 sensitive and 25 resistant cell lines), and hematopoietic tumors (BA = 0.94 for 16 sensitive and 13 resistant cell lines).